emiplacel (PLX-PAD) / Charite - University of Medicine Berlin, Pluri  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
emiplacel (PLX-PAD) / Pluri, Charite - University of Medicine Berlin
NCT04614025: Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19

Terminated
2a
23
Europe, RoW
PLX-PAD
Pluristem Ltd.
COVID, ARDS
08/21
02/23
2011-004091-12: A Clinical Study to Evaluate the Safety and Efficacy of Injections of Cells from another person for the Treatment of Subjects with Intermittent Claudication (IC).

Ongoing
2
150
Europe
PLX-PAD, adherent stromal cells (ASC), Suspension for injection
Pluristem Ltd., Pluristem Ltd.
Intermittent Claudication (IC); Fontaine class IIb; Rutherford category 2-3, Intermittent Claudication (IC) (Peripheral arterial occlusive disease); Fontaine class IIb; Rutherford category 2-3, Diseases [C] - Cardiovascular Diseases [C14]
 
 
NCT04389450: Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

Terminated
2
66
US
PLX-PAD, Placebo
Pluristem Ltd.
COVID, ARDS
05/21
06/23
2020-001857-31: A clinical study to test if a drug called PLX-PAD is both safe and can help in the treatment of COVID-19 patients

Not yet recruiting
2
40
Europe, RoW
PLX-PAD, Dispersion for injection
Pluristem Ltd., Pluristem Ltd.
Pneumonia or Acute Respiratory Distress Syndrome (ARDS) caused by severe COVID-19 disease, COVID-19–related critical illness, Diseases [C] - Virus Diseases [C02]
 
 

Download Options